BNP Paribas Financial Markets’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-16,855
| Closed | -$255K | – | 4969 |
|
|
2022
Q3 | $255K | Buy |
16,855
+6,362
| +61% | +$73.9K | ﹤0.01% | 3377 |
|
|
2022
Q2 | $78.7K | Sell |
10,493
-1,630
| -13% | -$11.5K | ﹤0.01% | 3428 |
|
|
2022
Q1 | $110K | Buy |
12,123
+3,131
| +35% | +$24.1K | ﹤0.01% | 3335 |
|
|
2021
Q4 | $63.1K | Buy |
8,992
+1,401
| +18% | +$14.7K | ﹤0.01% | 3697 |
|
|
2021
Q3 | $86.5K | Buy |
7,591
+5,932
| +358% | +$86.7K | ﹤0.01% | 3330 |
|
|
2021
Q2 | $26.6K | Sell |
1,659
-3,211
| -66% | -$55.1K | ﹤0.01% | 3464 |
|
|
2021
Q1 | $87K | Sell |
4,870
-2,206
| -31% | -$38.1K | ﹤0.01% | 3411 |
|
|
2020
Q4 | $95.6K | Sell |
7,076
-1,525
| -18% | -$18.4K | ﹤0.01% | 3231 |
|
|
2020
Q3 | $101K | Buy |
8,601
+6,211
| +260% | +$75.6K | ﹤0.01% | 3111 |
|
|
2020
Q2 | $35.3K | Sell |
2,390
-11,764
| -83% | -$174K | ﹤0.01% | 3176 |
|
|
2020
Q1 | $191K | Buy |
14,154
+8,124
| +135% | +$154K | ﹤0.01% | 2881 |
|
|
2019
Q4 | $146K | Sell |
6,030
-1,580
| -21% | -$32.7K | ﹤0.01% | 3104 |
|
|
2019
Q3 | $146K | Buy |
7,610
+2,626
| +53% | +$60.2K | ﹤0.01% | 2916 |
|
|
2019
Q2 | $147K | Sell |
4,984
-3,498
| -41% | -$135K | ﹤0.01% | 2802 |
|
|
2019
Q1 | $403K | Buy |
8,482
+7,437
| +712% | +$327K | ﹤0.01% | 2244 |
|
|
2018
Q4 | $37.7K | Sell |
1,045
-1,211
| -54% | -$56.8K | ﹤0.01% | 2855 |
|
|
2018
Q3 | $139K | Buy |
2,256
+287
| +15% | +$18.4K | ﹤0.01% | 2574 |
|
|
2018
Q2 | $133K | Sell |
1,969
-5,410
| -73% | -$303K | ﹤0.01% | 2644 |
|
|
2018
Q1 | $400K | Buy |
7,379
+453
| +7% | +$25.3K | ﹤0.01% | 2361 |
|
|
2017
Q4 | $414K | Buy |
6,926
+3,220
| +87% | +$195K | ﹤0.01% | 2582 |
|
|
2017
Q3 | $180K | Sell |
3,706
-5
| -0.1% | -$273 | ﹤0.01% | 2508 |
|
|
2017
Q2 | $195K | Buy |
3,711
+3,579
| +2,711% | +$167K | ﹤0.01% | 2465 |
|
|
2017
Q1 | $5.99K | Sell |
132
-331
| -71% | -$14.8K | ﹤0.01% | 3279 |
|
|
2016
Q4 | $17.5K | Sell |
463
-1,197
| -72% | -$45.3K | ﹤0.01% | 3241 |
|
|
2016
Q3 | $62.6K | Buy |
1,660
+723
| +77% | +$15.9K | ﹤0.01% | 2330 |
|
|
2016
Q2 | $16.5K | Buy |
+937
| New | +$15.2K | ﹤0.01% | 2671 |
|
|
2016
Q1 | – | Sell |
-4,032
| Closed | -$98.2K | – | 3197 |
|
|
2015
Q4 | $98.2K | Sell |
4,032
-506
| -11% | -$11.8K | ﹤0.01% | 2345 |
|
|
2015
Q3 | $80.5K | Buy |
4,538
+2,831
| +166% | +$51.3K | ﹤0.01% | 2522 |
|
|
2015
Q2 | $30.1K | Buy |
1,707
+1,460
| +591% | +$26.8K | ﹤0.01% | 2793 |
|
|
2015
Q1 | $7.74K | Buy |
+247
| New | +$7.16K | ﹤0.01% | 2894 |
|
|
2014
Q4 | – | Sell |
-762
| Closed | -$15.8K | – | 3420 |
|
|
2014
Q3 | $15.8K | Buy |
762
+613
| +411% | +$12.1K | ﹤0.01% | 3330 |
|
|
2014
Q2 | $3.69K | Buy |
149
+136
| +1,046% | +$2.36K | ﹤0.01% | 2760 |
|
|
2014
Q1 | $204 | Sell |
13
-82
| -86% | -$1.66K | ﹤0.01% | 3209 |
|
|
2013
Q4 | $1.71K | Buy |
+95
| New | +$1.24K | ﹤0.01% | 3727 |
|
BNP Paribas Financial Markets's AERI Position: Q4 2022 in Review
BNP Paribas Financial Markets sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 16,855 shares — an estimated $255K sold.
BNP Paribas Financial Markets first reported a position in AERI in Q4 2013 and held it in 34 quarters. The position peaked at $414K in Q4 2017. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- BNP Paribas Financial Markets reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- BNP Paribas Financial Markets sold 16,855 Aerie Pharmaceuticals shares in Q4 2022, an estimated $255K.
- BNP Paribas Financial Markets first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 34 quarters.
- BNP Paribas Financial Markets's Aerie Pharmaceuticals position peaked at $414K in Q4 2017.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.